REG - LungLife AI, INC - Cancellation & Reissue Share Options, PDMR Notice

LungLife AIAnnouncement

22/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241022:nRSV0293Ja&default-theme=true

RNS Number : 0293J  LungLife AI, INC  22 October 2024

22 October 2024

 

LungLife AI, Inc

("LungLife" or the "Company")

Cancellation and Reissue of Share Options / PDMR Notification

Further to the Company's announcement on 04 October 2024, LungLife AI (AIM:
LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms
that it has now completed the cancellation and re-issue of certain options as
detailed in that announcement.

As two of the affected option holders are persons discharging managerial
responsibilities, dealings disclosures for the purposes of the Market Abuse
Regulation are set out below.

For further information, please contact:

 LungLife AI, Inc.                                   www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                    via investors@lunglifeai.com
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Lydia Zychowska/ Sara Wallace

 Goodbody (Joint Broker)                             Tel: +44 (0) 20 3841 6202
 Tom Nicholson / Cameron Duncan

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

The notification set out below is provided in accordance with the requirements
of MAR.

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         1.   Paul Pagano

                                                                   2.   David Anderson

 2    Reason for the notification

 a)   Position/status                                              1.   Chief Executive Officer

                                                                   2.   Chief Financial Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         LungLife AI, Inc.

 b)   LEI                                                          549300VBVDIF0Y3OVI38

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Options over Ordinary Shares

      Identification code                                          ISIN: USU5500L1045

 b)   Nature of the transaction                                    Cancellation and re-issue of Options over Ordinary Shares pursuant to the 2021

                                                            Omnibus Long Term Incentive Plan

 c)   Price(s) and volume(s)

                                                                                         Price                 Volume(s)
                                                                                         1.   Nil              769,707
                                                                                         2.   Nil              386,703

 d)   Aggregated information                                       N/A

      - Aggregated volume

      - Price

 e)   Date of the transaction                                      18 October 2024

 f)   Place of the transaction                                     Outside of a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCVFLFLZBLFFBQ